Food and Drug Administration

Oncologic Drugs Advisory Committee

July 27, 2004


Alimta® (Pemetrexed) as a Second-Line Treatment for Patients With Non-Small Cell Lung Cancer, Dr. Paolo Paoletti, MD, Eli Lilly and Co. (HTM) (PPT)

Backup Slides, Eli Lilly and Co. (HTM) (PPT)

Presentation by Dr. Martin Cohen, MD, FDA (HTM) (PPT)

Efficacy Analyses - Alimta (NDA 21-677) Review, Yong-Cheng Wang, FDA (HTM) (PPT)

Open Public Hearing

Open Public Hearing Speakers (HTM) (PPT)

Questions to the Committee (HTM) (PPT)